ALW-II-41-27, an EphA2 inhibitor, inhibits proliferation, migration and invasion of cervical cancer cells via inhibition of the RhoA/ROCK pathway

Recent reports have proven the Eph receptor A2 (EphA2) and it is inhibitor ALW-II-41-27 could regulate various cellular processes in several kinds of cancer. However, the way ALW-II-41-27 affects the introduction of cervical cancer (CC) remains unknown. The current study aimed to judge the function of ALW-II-41-27 in inhibiting the proliferation, invasion and migration of human papilloma virus-positive CC cells and also to verify whether Ras homolog member of the family A (RhoA)/Rho-connected protein kinase (ROCK) can be a crucial path involved with this method. Reverse transcription-quantitative PCR and western blotting analyses indicated an upregulation of EphA2 expression in CC cell lines (HeLa and CaSki). In addition, the outcomes from MTT and colony formation assays established that ALW-II-41-27 inhibited cell proliferation. Is a result of wound healing and Transwell assays further shown the inhibitory aftereffect of ALW-II-41-27 on CaSki and HeLa cell migration and invasion, correspondingly. In addition, ALW-II-41-27 inhibited the protein expression of GTP-RhoA and ROCK1 in CaSki and HeLa cells. Additionally, the ALW-II-41-27-caused inhibition from the biological purpose of CaSki and HeLa cells was promoted by cell co-culture with RhoA and ROCK inhibitors. Taken together, the current findings says ALW-II-41-27 inhibited CC cell proliferation, migration and invasion by blocking the RhoA/ROCK path. These bits of information provide further understanding of the mechanism of CC progression and significant information ALW II-41-27 to add mass to potential therapeutic targets for CC.